CRIS Stock Summary and Trading Ideas (Curis | NASDAQ:CRIS)

Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

Curis trades on the NASDAQ stock market under the symbol CRIS.

As of July 8, 2026, CRIS stock price declined to $4.73 with 62,091 million shares trading.

CRIS has a beta of 3.41, meaning it tends to be more sensitive to market movements. CRIS has a correlation of 0.28 to the broad based SPY ETF.

CRIS has a market cap of $9.22 million. This is considered a Sub-Micro Cap stock.

Last quarter Curis reported $0 in Revenue and -$1.25 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$.98.

In the last 3 years, CRIS traded as high as $18.00 and as low as $.18.

The top ETF exchange traded funds that CRIS belongs to (by Net Assets): VTI, VXF.

CRIS has outperformed the market in the last year with a price return of +171.8% while the SPY ETF gained +20.6%. CRIS has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +760.2% and +1207.7%, respectively, while the SPY returned +12.7% and +1.0%, respectively.

CRIS support price is $4.65 and resistance is $5.93 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRIS shares will trade within this expected range on the day.